Sitafloxacin
Alternative Names: DU 6859; DU-6859a; Gracevit; Sitafloxacin hydrateLatest Information Update: 05 Nov 2023
At a glance
- Originator Daiichi Sankyo Company
- Class Antibacterials; Fluoroquinolones
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bacterial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers) in China (PO, Tablet)
- 28 Jun 2013 Daiichi Sankyo plans a phase I trial in Healthy volunteers in China
- 22 Apr 2013 Launched prior to this date for Bacterial infections in Thailand (PO)